AgeneBio Founder Michela Gallagher Presents Hope4MCI Results at 12th Alzheimer’s & Parkinson’s Drug Development Summit

« back to Press Releases Examining Progression in MCI Due to AD: Results from a Phase 2b Trial of AGB101 Using high resolution structural brain imaging to monitor brain atrophy as a biomarker of progression Consistent with a decrease in clinical and cognitive progression (CDR sum of boxes), brain atrophy was reduced by AGB101 compared to placebo in a 78-week double-blind randomized controlled study Topography of this effect was consistent with the prodromal phase of amnestic MCI (e.g. reducing atrophy of entorhinal cortex)

The release as fetched from its publisher. agenebio.com ↗